Read by QxMD icon Read

Estrogen therapy

Zhen Wang, Xiao Chen, Yongqiang Zhao, Yi Jin, Jia Zheng
BACKGROUND: Emerging evidences show that G-protein-coupled estrogen receptor (GPER) can regulate the progression of various cancers, while its roles in the progression of osteosarcoma (OS) are not well illustrated. METHODS: The expression of GPER in OS cells and tissues were checked. Its roles in cell migration and expression of Snail was checked by use of its agonist G-1. RESULTS: We found that the expression of GPER in OS cells and tissues were lower than that in their corresponding controls...
October 20, 2018: Journal of Cancer Research and Clinical Oncology
Mohammad Selim, Amandeep Rakhra, Thamer Kassim, Rouhin Sen, Javaneh Jabbari, Carrie Valenta
A case of 43-year-old female presented to the emergency department (ED) with a new onset grand mal tonic-clonic seizure lasting at least two minutes with post-ictal confusion. Imaging was consistent with cerebral sinus venous thrombosis (CSVT) associated with intracranial hemorrhage. After ruling out most common causes of thrombosis, the etiology was attributed to estrogen vaginal ring. The patient was treated with anticoagulation therapy and had increasing hemorrhagic changes in the first few days, which eventually improved...
August 5, 2018: Curēus
Kevin Chang, Anita Lwanga, Tanjeev Kaur, Cathy Helgason
Paraneoplastic neurologic syndromes are a group of immune-mediated, cancer-associated disorders affecting the nervous system. While these syndromes are not understood fully, they are reportedly caused by an immune response against common antigens expressed by the cancer and nervous system. We describe the course of a patient who suffered paraneoplastic chorea before being diagnosed with breast cancer. A 70-year-old female presented with complaints of "shaking" movements of her head. History, physical exam findings, and preliminary workup ruled out the hereditary, metabolic, and infectious causes of chorea while brain computed tomography (CT) ruled out chorea due to a basal ganglia lesion...
August 4, 2018: Curēus
David Austin, Nalo Hamilton, Yahya Elshimali, Richard Pietras, Yanyuan Wu, Jaydutt Vadgama
Triple Negative breast cancer (TNBC) is a subtype of breast cancer that lacks the expression of estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2. TNBC accounts for 15-20% of all breast cancer cases but accounts for over 50% of mortality. We propose that Estrogen receptor-beta (ERβ) and IGF2 play a significant role in the pathogenesis of TNBCs, and could be important targets for future therapy. Tissue microarrays (TMAs) from over 250 TNBC patients' were analyzed for ERβ and IGF2 expression by immunohistochemistry...
September 21, 2018: Oncotarget
Hongyan Yuan, Levy Kopelovich, Yuzhi Yin, Jin Lu, Robert I Glazer
[This corrects the article DOI: 10.18632/oncotarget.457.].
September 18, 2018: Oncotarget
Tae-Hee Kim, Jong Ho Choi, Yesl Jun, Seung Mook Lim, Sohae Park, Jin-Young Paek, Sang-Hoon Lee, Ji-Young Hwang, Gi Jin Kim
Placenta-derived mesenchymal stem cells (PD-MSCs) have numerous advantages over other adult MSCs that make them an attractive cell source for regenerative medicine. Here, we demonstrate the therapeutic effect of PD-MSCs in ovariectomized (Ovx) rats and compare their efficacy when generated via a conventional monolayer culture system (2D, naïve) and a spheroid culture system (3D, spheroid). PD-MSC transplantation significantly increased the estradiol level in Ovx rats compared with the non-transplantation (NTx) group...
October 17, 2018: Scientific Reports
Joanna Picot, Neelam Kalita, Wendy Gaisford, Petra Harris, Oluchukwu Onyimadu, Keith Cooper
Clinical and cost-effectiveness evidence on fulvestrant for untreated hormone-receptor positive locally advanced or metastatic breast cancer was submitted to the single technology appraisal process of the National Institute for Health and Care Excellence by the manufacturer of fulvestrant. The Southampton Health Technology Assessments Centre was commissioned by the National Institute for Health and Care Excellence as an independent Evidence Review Group to critique the company's submitted evidence. Fulvestrant was compared directly with anastrozole in two randomised controlled trials and was compared indirectly by means of a network meta-analysis with anastrozole, letrozole and tamoxifen...
October 17, 2018: PharmacoEconomics
Masafumi Iida, Kouki Tsuboi, Toshifumi Niwa, Takanori Ishida, Shin-Ichi Hayashi
BACKGROUND: Hormone therapy targeting the estrogen receptor (ER) pathway is the most common treatment used for ER-positive breast cancer. However, some patients experience de novo or acquired resistance, which becomes a critical problem. Activation of the insulin-like growth factor (IGF) pathway allows breast cancer cells to proliferate and is associated with the ER pathway. Little is known about the role of the IGF pathway in hormone therapy and resistance; therefore, we investigated whether the inhibition of this pathway may represent a novel therapeutic target for overcoming hormone therapy resistance in ER-positive breast cancers...
October 16, 2018: Breast Cancer: the Journal of the Japanese Breast Cancer Society
Beth Z Clark, Agnieszka Onisko, Binara Assylbekova, Xin Li, Rohit Bhargava, David J Dabbs
Biomarker analysis of invasive breast carcinoma is useful for prognosis, as surrogate for molecular subtypes of breast cancer, and prediction of response to adjuvant and neoadjuvant systemic therapies. Breast cancer intratumoral heterogeneity is incompletely studied. Comprehensive biomarker analysis of estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67 labeling index was performed on each tissue block of 100 entirely submitted breast tumors in 99 patients. Invasive carcinoma and in situ carcinoma was scored using semiquantitative histologic score (H-score) for ER and PR, HER2 expression from 0 to 3+, and percentage positive cells for Ki67...
October 16, 2018: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
Jenifer Freitas Campos, Aline Gomes Hidalgo Mierzwa, Mariana Freitas-Jesus, Marise Lazaretti-Castro, Keico Okino Nonaka, Rejane Daniele Reginato
INTRODUCTION: Intermittent 1-34 parathyroid hormone (iPTH) administration, a bone-forming treatment, is widely used as a therapy for severe osteoporosis. It can only be used for a maximum of 24 mo and must be followed by an antiresorptive drug to retain the new formed tissue. Mechanical load, in the form of low-intensity and high-frequency vibration, has received considerable attention due to its ability to prevent bone loss. AIM: To investigate the ability of whole body mechanical vibration (MV) to potentiate the anabolic effects of iPTH and to inhibit bone resorption following discontinuation of iPTH treatment in estrogen-deficient rats...
September 8, 2018: Journal of Clinical Densitometry
Nela Van Donge, Natasha A Schvey, Timothy A Roberts, David A Klein
Introduction: Transgender and gender-diverse (TGD) youth are at greater risk for mental health and medical conditions than their cisgender peers; however, poor health outcomes and identity-based discrimination can be minimized in the context of optimal support. Approximately 1.7 million youth may be eligible for care covered by the Military Health System, which includes mental health and gender-affirming medications. The purpose of the current study is to identify sociodemographic characteristics, the psychosocial and behavioral risk profile, and health care utilization patterns of TGD dependent youth cared for in the U...
October 16, 2018: Military Medicine
Angeles C Tecalco-Cruz, Josue O Ramirez-Jarquin, Eduardo Cruz-Ramos
More than 70% of all breast cancer cases are estrogen receptor alpha-positive (ERα). ERα is a member of the nuclear receptor family, and its activity is implicated in the gene transcription linked to the proliferation of breast cancer cells, as well as in extranuclear signaling pathways related to the development of resistance to endocrine therapy. Several protein-protein interactions and post-translational modifications of ERα represent critical mechanisms that modulate its activity...
October 15, 2018: Current Drug Targets
C Liedtke, Hans-Christian Kolberg, L Kerschke, D Görlich, I Bauerfeind, T Fehm, B Fleige, G Helms, A Lebeau, A Stäbler, S Schmatloch, M Hausschild, L Schwentner, Gunter von Minckwitz, S Loibl, M Untch, T Kühn
Optimization of axillary staging among patients converting from clinically node-positive disease to clinically node-negative disease through primary systemic therapy is needed. We aimed at developing a nomogram predicting the probability of positive axillary status after chemotherapy based on clinical/pathological parameters. Patients from study arm C of the SENTINA trial were included. Univariable/multivariable analyses were performed for 13 clinical/pathological parameters to predict a positive pathological axillary status after chemotherapy using logistic regression models...
October 15, 2018: Clinical & Experimental Metastasis
S Rozenberg, A Joris, V Albert, C Antoine, J Vandromme
Postmenopausal hormone therapy (MHT) is mainly used for the relief of menopausal symptoms. It can also be prescribed for the treatment of postmenopausal osteoporosis, but nowadays, other medications are given to older patients for this indication. Current, available data, demonstrates that MHT is beneficial as well as safe for postmenopausal, symptomatic women. Modern regimens of MHT comprise lower dosages of estrogens than in the past, either safer progestins or SERMs. These regimens should be the preferred option for women with a uterus...
2018: Revue Médicale de Bruxelles
Motoaki Yasukawa, Tomoko Uchiyama, Chiho Ohbayashi, Takeshi Kawaguchi, Norikazu Kawai, Noriyoshi Sawabata, Shigeki Taniguchi
A mediastinal Müllerian cyst is composed of heterotopic cystic Müllerian tissue resembling structures of the fallopian tube. We herein report a case of a mediastinal Müllerian cyst discovered during a medical check-up of a 41-year-old woman. She had no symptoms but had been diagnosed with hyperprolactinemia at the age of 24 years, for which she received hormonal therapy for 3 years. Chest computed tomography demonstrated a 3-cm-diameter cystic tumor in front of the Th10 vertebra. Thoracic surgery was performed to remove the tumor...
November 2018: Oxford Medical Case Reports
Sabina Bhatta, Jeffrey A Blair, Gemma Casadesus
Pervasive age-related dysfunction in hypothalamic-pituitary-gonadal (HPG) axis is associated with cognitive impairments in aging as well as pathogenesis of age-related neurodegenerative diseases such as the Alzheimer's disease (AD). As a major regulator of the HPG axis, the steroid hormone estrogen has been widely studied for its role in regulation of memory. Although estrogen modulates both cognition as well as cognition associated morphological components in a healthy state, the benefits of estrogen replacement therapy on cognition and disease seem to diminish with advancing age...
2018: Frontiers in Endocrinology
Gabrielle B Rocque, Courtney P Williams, Kelly M Kenzik, Bradford E Jackson, Andres Azuero, Karina I Halilova, Stacey A Ingram, Maria Pisu, Andres Forero, Smita Bhatia
BACKGROUND: The impact of National Comprehensive Cancer Network (NCCN) treatment guideline concordance on costs, health care utilization, and mortality for patients with breast cancer and secondary metastases is unknown. METHODS: From 2007 to 2013, women with early-stage breast cancer who received treatment for secondary metastases (n = 5651) were evaluated for first recorded systemic therapy concordance with NCCN guidelines within the Surveillance, Epidemiology, and End Results Program-Medicare linked database...
October 14, 2018: Cancer
Tatsuro Yamamoto, Chiyomi Sakamoto, Hiroaki Tachiwana, Mitsuru Kumabe, Toshiro Matsui, Tadatoshi Yamashita, Masatoshi Shinagawa, Koji Ochiai, Noriko Saitoh, Mitsuyoshi Nakao
Long-term estrogen deprivation (LTED) of an estrogen receptor (ER) α-positive breast cancer cell line recapitulates cancer cells that have acquired estrogen-independent cell proliferation and endocrine therapy resistance. Previously, we have shown that a cluster of non-coding RNAs, Eleanors (ESR1 locus enhancing and activating non-coding RNAs) formed RNA cloud and upregulated the ESR1 gene in the nuclei of LTED cells. Eleanors were inhibited by resveratrol through ER. Here we prepared another polyphenol, glyceollin I from stressed soybeans, and identified it as a major inhibitor of the Eleanor RNA cloud and ESR1 mRNA transcription...
October 12, 2018: Scientific Reports
Melissa A Maczis, Michael Maceyka, Michael R Waters, Jason Newton, Manjulata Singh, Madisyn F Rigsby, Tia H Turner, Mohammad A Alzubi, J Chuck Harrell, Sheldon Milstien, Sarah Spiegel
In breast cancer, 17β-estradiol (E2) plays critical roles mainly by binding to its canonical receptor, estrogen receptor (ER) α66, and eliciting genomic effects. E2 also triggers rapid, non-genomic responses. E2 activates sphingosine kinase 1 (SphK1), increasing sphingosine-1-phosphate (S1P) that binds to its receptors leading to important breast cancer signaling. However, the E2 receptor responsible for SphK1 activation has not yet been identified. Here we demonstrate in triple negative breast cancer cells, which lack the canonical ERα66 but express the novel splice variant ERα36, that ERα36 is the receptor responsible for E2-induced activation of SphK1 and formation and secretion of S1P and dihydro-S1P, the ligands for S1PRs...
October 12, 2018: Journal of Lipid Research
Sarah Croessmann, Luigi Formisano, Lisa Kinch, Paula I Gonzalez-Ericsson, Dhivya R Sudhan, Rebecca J Nagy, Aju Mathew, Eric H Bernicker, Massimo Cristofanilli, Jie He, Richard E Cutler, Alshad S Lalani, Vincent A Miller, Richard B Lanman, Nick Grishin, Carlos L Arteaga
PURPOSE: We examined the role of ERBB2 activating mutations in endocrine therapy resistance in estrogen receptor positive (ER+) breast cancer. Design ERBB2 mutation frequency was determined from large genomic databases. Isogenic knock-in ERBB2 mutations in ER+ MCF7 cells and xenografts were used to investigate estrogen-independent growth. Structural analysis was used to determine the molecular interaction of HER L755S with HER3. Small molecules and siRNAs were used to inhibit PI3Kα, TORC1 and HER3...
October 12, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"